Form 4: Fennec Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Jeffrey S. Hackman, Chief Executive Officer and a Director of Fennec Pharmaceuticals Inc., received 2,224 shares of common stock on October 12, 2026.
Summary
- Grant/award: acquired 2,224 Common Shares at $5.53 ($12,299) on October 12, 2026; holds 69,685 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jeffrey S. Hackman — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-12 | Grant/award | Common Shares | 2,224 | $6 | $12.3K | 69,685 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-12 | Grant/award (2,224 shares) |
Keywords
insider transaction, Form 4, FENC, FENNEC PHARMACEUTICALS INC., neutral, Jeffrey S. Hackman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.